Biotechnology

With fresh funding, Primmune is advancing its unique TLR7 agonist, designed for efficacy without severe side effects, into a pivotal melanoma trial in Australia.

A first-in-class oral therapy targeting cellular metabolism has entered patient trials, offering new hope for a disease-modifying treatment for eczema.

Janux Therapeutics appoints Dr. William Go, a key leader behind YESCARTA®'s approval, as CMO to steer its novel immunotherapy pipeline through critical trials.

A new partnership between Mair Therapeutics and Radboud University aims to fix the cell's waste disposal system, a novel approach for Parkinson's disease.

Following impressive Phase 2 results, Scancell's novel immunotherapy iSCIB1+ receives FDA clearance for a pivotal trial, offering new hope for patients.

A new partnership aims to accelerate a pipeline of innovative multi-functional fusion proteins, potentially reshaping treatment for cancer and autoimmune disease.

Flexible Solutions posts modest 2025 revenue gains, but a major strategic shift to food-grade products and new factories sets the stage for a breakout year.

Researchers discover a potent, natural moisturizer from Indonesian seaweed, promising a sustainable and safer alternative to synthetic skincare ingredients.

A new Canadian patent for a metformin-based eye drop could revolutionize treatment for degenerative eye diseases in both humans and their canine companions.

Insilico Medicine's AI-powered drug ISM8969, a brain-penetrant inhibitor, has been cleared by the FDA for clinical trials in Parkinson's disease.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.

With strong Q1 momentum, Standex faces a complex market. Its upcoming Q2 results will offer key insights into global manufacturing and corporate strategy.

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

With promising results in tough-to-treat colorectal cancer, a strong cash runway, and key alliances, Adagene is poised for a pivotal year.

Acrivon Therapeutics to unveil pivotal data showing high response rates for its targeted drug ACR-368 in an aggressive endometrial cancer subtype.

A single patient with a debilitating eye pain condition gains access to an investigational therapy, offering hope where no approved treatments exist.

New 24-month data suggests a novel drug could improve kidney function and reduce side effects for transplant patients, challenging a decades-old standard.

Ossium Health's groundbreaking study using banked bone marrow from deceased donors could solve the critical shortage of transplant matches for patients.

Swiss biotech GeNeuro suspends trading, awaiting a critical court ruling on its debt moratorium that will decide its fate and the future of its novel drugs.

Frost & Sullivan recognizes Verana Health as the top innovator in real-world evidence, a move solidifying its market dominance after a key oncology merger.